Prostate Cancer Recurrence After Surgery Linked to Pelvic Inflammation
A recent study is the first to examine the association between pelvic inflammation and prostate cancer biology and outcomes.
A recent study is the first to examine the association between pelvic inflammation and prostate cancer biology and outcomes.
68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show.
Real-world data validate recently reported findings from clinical trials.
Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.
Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
Findings from a new study can help individualize prognoses for men with biochemical recurrence of prostate cancer after radical prostatectomy.
Separate studies demonstrated that partial nephrectomy could be an acceptable alternative to radical nephrectomy in selected cases of high-risk kidney cancer and large renal masses.